In the US, asthma affects over ... National Medical (TASE:BLWV) Products Administration, following positive phase III trial results. These developments reflect GSK’s ongoing efforts to advance ...

GSK plc (NYSE:GSK) specializes in pharmaceuticals, vaccines, and consumer health products, with a strong focus on immunology.

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

"Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma ... products. It is one of five key product launches that ...

The growth of these products comes from strong patient demand. These two long-acting medicines contributed more than 50% of the total HIV growth and now account for 20% of HIV sales. In 2025, GSK ...

GSK's revenue and EPS exceeded my expectations ... with a frequency of use only once every six months for the treatment of asthma and CRSwNP [chronic rhinosinusitis with nasal polyps], and ...

plus another asthma controller. GSK is also looking to get the candidate approved as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with ...

The findings, presented at the 2025 American Academy of Allergy, Asthma ... Products Administration, based on promising results from the Phase III MATINEE trial. In corporate governance ...

GSK's severe asthma therapy Nucala could find a new lease ... The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year, up 15%.

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ...